Melanoma-associated antigen 3-derived epitopes (MAGEA3 epitopes)

MAGEA3-derived epitopes are peptide fragments from the Melanoma-associated antigen 3 protein, a member of the cancer-testis antigen family (UniProt: P43357). These epitopes are presented on the surface of cancer cells by Major Histocompatibility Complex (MHC) class I molecules, such as HLA-A1 or HLA-A2, allowing them to be recognized by CD8+ T-cells. Because MAGEA3 is typically expressed only in immune-privileged sites like the testes and is aberrantly overexpressed in various cancers, these epitopes serve as highly specific targets for immunotherapy. Therapeutic approaches have included recombinant protein vaccines and engineered T-cell receptor (TCR) therapies aimed at inducing a robust anti-tumor immune response. Despite their potential, clinical trials have encountered hurdles, including the failure of large-scale vaccine trials like MAGRIT to meet primary endpoints (PubMed: 27071706). Furthermore, fatal off-target toxicities have occurred where TCRs targeting MAGEA3 epitopes cross-reacted with the muscle protein Titin in the heart (PubMed: 23908459) or MAGE-A12 in the brain (PubMed: 21422440), highlighting the critical need for stringent specificity in epitope-based drug design.

Other names

MAGE-3 epitopesMAGE-A3 peptidesMelanoma antigen family A 3 epitopesCancer/testis antigen 1.3 epitopes

Stimulation of antigen-specific cytotoxic T-lymphocytes through MHC-restricted peptide recognition